These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

308 related items for PubMed ID: 11944697

  • 1. Long-term effect of interferon therapy on incidence of cirrhosis and hepatocellular carcinoma in Thai patients with chronic hepatitis B.
    Tangkijvanich P, Thong-ngam D, Mahachai V, Kladchareon N, Suwangool P, Kullavanijaya P.
    Southeast Asian J Trop Med Public Health; 2001 Sep; 32(3):452-8. PubMed ID: 11944697
    [Abstract] [Full Text] [Related]

  • 2. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy.
    Shindo M, Ken A, Okuno T.
    Cancer; 1999 May 01; 85(9):1943-50. PubMed ID: 10223234
    [Abstract] [Full Text] [Related]

  • 3. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection.
    Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF.
    Hepatology; 1999 Mar 01; 29(3):971-5. PubMed ID: 10051505
    [Abstract] [Full Text] [Related]

  • 4. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
    Papatheodoridis GV, Manolakopoulos S, Touloumi G, Vourli G, Raptopoulou-Gigi M, Vafiadis-Zoumbouli I, Vasiliadis T, Mimidis K, Gogos C, Ketikoglou I, Manesis EK, HEPNET. Greece Cohort Study Group.
    Gut; 2011 Aug 01; 60(8):1109-16. PubMed ID: 21270118
    [Abstract] [Full Text] [Related]

  • 5. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma.
    Lin SM, Yu ML, Lee CM, Chien RN, Sheen IS, Chu CM, Liaw YF.
    J Hepatol; 2007 Jan 01; 46(1):45-52. PubMed ID: 17107734
    [Abstract] [Full Text] [Related]

  • 6. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.
    Yu ML, Lin SM, Chuang WL, Dai CY, Wang JH, Lu SN, Sheen IS, Chang WY, Lee CM, Liaw YF.
    Antivir Ther; 2006 Jan 01; 11(8):985-94. PubMed ID: 17302368
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis.
    Yang YF, Zhao W, Zhong YD, Xia HM, Shen L, Zhang N.
    J Viral Hepat; 2009 Apr 01; 16(4):265-71. PubMed ID: 19220736
    [Abstract] [Full Text] [Related]

  • 9. [Study on the natural history of chronic hepatitis B].
    Wu G, Zhou W, Zhao Y, Guo S, Wang Z, Zou S, Zhang Q, Ren H, Huang A, Zhang D.
    Zhonghua Gan Zang Bing Za Zhi; 2002 Feb 01; 10(1):46-8. PubMed ID: 11856503
    [Abstract] [Full Text] [Related]

  • 10. Long-term follow-up of Japanese patients with chronic hepatitis B treated with interferon-alpha.
    Truong BX, Seo Y, Kato M, Hamano K, Ninomiya T, Katayama M, Kato H, Yano Y, Hayashi Y, Kasuga M.
    Int J Mol Med; 2005 Aug 01; 16(2):279-84. PubMed ID: 16012762
    [Abstract] [Full Text] [Related]

  • 11. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon.
    Ikeda M, Fujiyama S, Tanaka M, Sata M, Ide T, Yatsuhashi H, Watanabe H.
    J Gastroenterol; 2005 Feb 01; 40(2):148-56. PubMed ID: 15770398
    [Abstract] [Full Text] [Related]

  • 12. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease.
    Yuen MF, Seto WK, Chow DH, Tsui K, Wong DK, Ngai VW, Wong BC, Fung J, Yuen JC, Lai CL.
    Antivir Ther; 2007 Feb 01; 12(8):1295-303. PubMed ID: 18240869
    [Abstract] [Full Text] [Related]

  • 13. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.
    van Zonneveld M, Honkoop P, Hansen BE, Niesters HG, Darwish Murad S, de Man RA, Schalm SW, Janssen HL.
    Hepatology; 2004 Mar 01; 39(3):804-10. PubMed ID: 14999700
    [Abstract] [Full Text] [Related]

  • 14. The natural history of chronic hepatitis B: a retrospective study.
    Wu GC, Zhou WP, Zhao YR, Guo SH, Wang ZY, Zou SB, Zhang QH, Ren H, Huang AL, Zhang DF.
    Hepatobiliary Pancreat Dis Int; 2003 Nov 01; 2(4):566-70. PubMed ID: 14627521
    [Abstract] [Full Text] [Related]

  • 15. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine.
    Di Marco V, Marzano A, Lampertico P, Andreone P, Santantonio T, Almasio PL, Rizzetto M, Craxì A, Italian Association for the Study of the Liver (AISF) Lamivudine Study Group, Italy.
    Hepatology; 2004 Oct 01; 40(4):883-91. PubMed ID: 15382125
    [Abstract] [Full Text] [Related]

  • 16. Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. European Concerted Action on Viral Hepatitis (EUROHEP).
    Fattovich G, Giustina G, Sanchez-Tapias J, Quero C, Mas A, Olivotto PG, Solinas A, Almasio P, Hadziyannis S, Degos F, de Moura MC, Krogsgaard K, Pantalena M, Realdi G, Corrocher R, Schalm SW.
    Am J Gastroenterol; 1998 Jun 01; 93(6):896-900. PubMed ID: 9647014
    [Abstract] [Full Text] [Related]

  • 17. Clinical and pathological factors associated with the development of hepatocellular carcinoma in patients with hepatitis virus-related cirrhosis: a long-term follow-up study.
    Rodríguez-Díaz JL, Rosas-Camargo V, Vega-Vega O, Morales-Espinosa D, Mendez-Reguera A, Martínez-Tlahuel JL, Gamboa-Domínguez A, Arrieta O.
    Clin Oncol (R Coll Radiol); 2007 Apr 01; 19(3):197-203. PubMed ID: 17359907
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Long-term evaluation of interferon therapy in hepatitis C virus-associated cirrhosis: does IFN prevent development of hepatocellular carcinoma?
    Tanaka K, Sata M, Uchimura Y, Suzuki H, Tanikawa K.
    Oncol Rep; 1998 Apr 01; 5(1):205-8. PubMed ID: 9458323
    [Abstract] [Full Text] [Related]

  • 20. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B.
    Hsu YS, Chien RN, Yeh CT, Sheen IS, Chiou HY, Chu CM, Liaw YF.
    Hepatology; 2002 Jun 01; 35(6):1522-7. PubMed ID: 12029639
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.